Telehealth companies are marketing GLP-1 drugs for addiction treatment. The U.S. Food and Drug Administration has not yet issued an official ruling on their efficacy for these conditions. STAT reports that startups including Quel, Livelyhood, and Choose Your Horizon are promoting off-label prescriptions of these popular obesity medications to individuals struggling with substance use. These providers target patients with alcohol use disorder. In this field, the drugs show promise but remain unverified by regulators for this specific application. Some providers even offer compounded versions of the medications that have not received approval from health authorities. This move allows private firms to bypass the standard regulatory timeline. They deliver treatments to consumers currently waiting for formal clinical validation.